Xylem Investing Cash Flow increased by 46.5% to -$76.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 406.7%, from -$15.00M to -$76.00M. Over 4 years (FY 2021 to FY 2025), Investing Cash Flow shows a downward trend with a 26.7% CAGR.
A negative value typically signals investment in future growth, while a positive value may indicate divestment or the maturity of a large investment portfolio.
This metric is the net total of all cash inflows and outflows related to investing activities, including capital expendi...
Most mature healthcare companies maintain a negative net investing cash flow due to ongoing R&D and infrastructure investment.
net_cash_from_investing| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$38.00M | -$44.00M | -$70.00M | -$43.00M | -$41.00M | -$39.00M | -$68.00M | -$37.00M | -$452.00M | -$50.00M | -$89.00M | -$51.00M | -$77.00M | -$65.00M | -$289.00M | -$15.00M | -$125.00M | -$189.00M | -$142.00M | -$76.00M |
| QoQ Change | — | -15.8% | -59.1% | +38.6% | +4.7% | +4.9% | -74.4% | +45.6% | <-999% | +88.9% | -78.0% | +42.7% | -51.0% | +15.6% | -344.6% | +94.8% | -733.3% | -51.2% | +24.9% | +46.5% |
| YoY Change | — | — | — | — | -7.9% | +11.4% | +2.9% | +14.0% | <-999% | -28.2% | -30.9% | -37.8% | +83.0% | -30.0% | -224.7% | +70.6% | -62.3% | -190.8% | +50.9% | -406.7% |